Related Experiment Video
Updated: Aug 1, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
Published on: May 15, 2014
Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration.
Insights
This study compared four smallpox vaccines in children. The CV-1 strain showed lower infectivity and potency compared to licensed vaccines, impacting immune responses.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Smallpox vaccination is crucial for preventing disease.
- Evaluating the efficacy and safety of different vaccine strains is essential.
Purpose of the Study:
- To compare the antigenicity and reactogenicity of four smallpox vaccines.
- To assess dose-response relationships and immune responses to different vaccine strains.
Main Methods:
- 786 children received primary percutaneous vaccination with three concentrations of four smallpox vaccine strains.
- Assessed vaccine potency, infectivity, lesion size, fever incidence, and antibody production (hemagglutination-inhibiting and neutralizing antibodies).
Main Results:
- Licensed vaccines (New York City, Lister) showed similar potencies; CV-1 strain was 10-fold less infectious and produced smaller lesions.
- CV-1 vaccination resulted in lower neutralizing antibody induction (30%) compared to licensed vaccines (82-85%).
- Minor complications were most frequent with New York City strains.
Conclusions:
- The CV-1 strain exhibits reduced immunogenicity and infectivity compared to licensed smallpox vaccines.
- Licensed vaccines demonstrate comparable potency and induce robust neutralizing antibody responses.
- Vaccine strain selection impacts reactogenicity and immune response, necessitating careful consideration in smallpox prevention strategies.
Abstract:
In an investigation of the antigenicity and reactogenicity of four smallpox vaccines, 786 children received primary percutaneous vaccination with vaccine in one of three concentrations, 10(6), 10(7), or10(8) pock-forming units/ml. Dose-response curves indicated that the three licensed vaccines (New York City Board of Health strains grown in calf lymph or chorioallantoic membrane, and the Lister vaccine) had similar potencies, but the CV-1 strain was about 10-fold less infectious. CV-1 also produced smaller skin lesions than the other three vaccines, and the incidence of fever in CV-1 vaccines who developed either "major reactions" or serum antibody was not significantly different from that in children in all vaccine groups with no evidence of "take." Hemmagglutination-inhibiting antibody was consistently seen in individuals who received potent New York City and Lister vaccines, and neutralizing antibody was induced in 82%-85% of children in this group who had some evidence of take (production of hemagglutination-inhibiting antibody or or major reaction). Only 30% of CV-1 vaccines with takes produced neutralizing antibody. Minor complications occurred in all groups, but most often in children who received the New York City strains."
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccines
Smallpox
Chickenpox
Poliomyelitis

